Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following:

• CD20-positive aggressive B-cell non-Hodgkin's lymphoma (NHL), including any of the following subtypes:

• Diffuse large cell lymphoma*, meeting 1 of the following criteria:

• Relapsed disease after initial therapy, but failed to mobilize or had bone marrow involvement and therefore is not suitable for an autologous stem cell transplantation
• High-intermediate- or high-risk second-line, age-adjusted International Prognostic Index score and in second complete remission (CR) or partial remission (PR) after autologous stem cell transplantation
• Failed prior autologous stem cell transplantation and in PR or better after salvage chemotherapy
• Large cell transformation of indolent NHL or chronic lymphocytic leukemia (CLL), meeting the following criteria:

• In CR or PR of the large cell component of disease after salvage chemotherapy or autologous stem cell transplantation
• Mantle cell lymphoma*, meeting 1 of the following criteria:

• High-risk disease (e.g., p53 positivity) and in first CR or PR after initial therapy
• Relapsed disease after initial therapy and in second or third CR or PR after salvage chemotherapy NOTE: *No progressive disease at allograft work-up
• CD20-positive indolent NHL (e.g., follicular lymphoma, small cell lymphoma, or marginal zone NHL) OR CLL

• Second or subsequent progression (pre-allograft cytoreduction necessary, but CR or PR not required)
• Relapsed disease must be biopsy-proven
• Must have received pre-allograft salvage chemotherapy, including 1 of the following:

• Single autologous stem cell transplantation using high-dose chemotherapy conditioning within the past 120 days
• At least 2 courses of intensive combination chemotherapy (e.g., RICE [rituximab, ifosfamide, carboplatin, etoposide]), according to diagnosis, within the past 80 days
• CLL patients who have received CAMPATH do not have to receive pre-allograft salvage chemotherapy
• HLA-compatible related or unrelated donor available

• HLA-matched ≥ 9/10 of the A, B, C, DRB1, and DQB1 loci, as tested by high resolution typing

• One allele mismatch allowed

PATIENT CHARACTERISTICS:

• Karnofsky performance status 70-100%
• Creatinine < 1.2 mg/mL OR creatinine clearance ≥ 50 mL/min
• Bilirubin < 2.5 mg/dL
• AST and ALT ≤ 3 times upper limit of normal (unless benign congenital hyperbilirubinemia is present)
• Spirometry and corrected DLCO ≥ 50% of normal
• LVEF ≥ 40%
• Albumin ≥ 2.5 g/dL
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No active uncontrolled infection, including active infection with Aspergillus or other mold
• No HIV infection
• No hepatitis B antibody or antigen positivity

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• No prior allogeneic transplantation